Shares of Dynavax Technologies Co. (NASDAQ:DVAX) hit a new 52-week low during trading on Monday . The company traded as low as $6.66 and last traded at $6.75, with a volume of 24878 shares trading hands. The stock had previously closed at $6.95.
A number of analysts have commented on the stock. Zacks Investment Research lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Monday. ValuEngine upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Finally, BidaskClub lowered shares of Dynavax Technologies from a “sell” rating to a “strong sell” rating in a research note on Monday, February 25th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Dynavax Technologies currently has an average rating of “Hold” and a consensus target price of $27.00.
The company has a debt-to-equity ratio of 1.60, a quick ratio of 4.08 and a current ratio of 4.58. The firm has a market capitalization of $430.08 million, a PE ratio of -2.64 and a beta of 0.67.
In other Dynavax Technologies news, SVP Robert Coffman sold 63,202 shares of Dynavax Technologies stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $9.03, for a total transaction of $570,714.06. Following the transaction, the senior vice president now directly owns 86,268 shares of the company’s stock, valued at approximately $779,000.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP David Louis Johnson sold 20,765 shares of Dynavax Technologies stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $9.03, for a total transaction of $187,507.95. Following the transaction, the vice president now directly owns 52,786 shares in the company, valued at $476,657.58. The disclosure for this sale can be found here. Insiders have sold a total of 119,411 shares of company stock worth $1,075,091 over the last ninety days. Insiders own 3.47% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of DVAX. Advisor Group Inc. boosted its holdings in shares of Dynavax Technologies by 515.3% in the 4th quarter. Advisor Group Inc. now owns 4,473 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 3,746 shares during the last quarter. Pacer Advisors Inc. purchased a new position in shares of Dynavax Technologies in the 3rd quarter worth about $132,000. Legal & General Group Plc boosted its holdings in shares of Dynavax Technologies by 18.7% in the 4th quarter. Legal & General Group Plc now owns 11,814 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,860 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Dynavax Technologies in the 4th quarter worth about $117,000. Finally, Wall Street Access Asset Management LLC boosted its holdings in shares of Dynavax Technologies by 7.0% in the 4th quarter. Wall Street Access Asset Management LLC now owns 15,300 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 1,000 shares during the last quarter. 84.11% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4299181/dynavax-technologies-dvax-reaches-new-52-week-low-at-6-66.html.
About Dynavax Technologies (NASDAQ:DVAX)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Featured Story: What is the Book Value of a Share?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.